World's Best Scientists 2026 revealed!
Jeffrey R. Infante

Jeffrey R. Infante

D-Index & Metrics

Medicine

D-Index
84
Citations
34168
World Ranking
14900
National Ranking
187

Overview

Jeffrey R. Infante is affiliated with Janssen (Belgium) and specializes in Medicine, with a primary focus on Oncology and related subfields. Their research contributions span multiple areas including Radiology, Nuclear Medicine and Imaging, Molecular Biology, Hematology, and Pulmonary and Respiratory Medicine.

Infante's research topics predominantly cover:

  • CAR-T cell therapy research
  • Multiple Myeloma research and treatments
  • Monoclonal and Polyclonal Antibodies research
  • Cancer Immunotherapy and Biomarkers
  • Cancer-related Molecular Pathways
  • Immunotherapy and Immune Responses
  • Lung Cancer treatments and mutations

Frequent co-authors collaborating with Infante include:

  • Arnob Banerjee
  • Suzette Girgis
  • Tara Stephenson
  • Yusri Elsayed
  • Jenna D. Goldberg

The scientist has published multiple papers in notable venues. The most frequent publication venues for their work are:

  • Clinical Cancer Research
  • The Lancet
  • Blood
  • Journal of Clinical Oncology
  • Targeted Oncology

Selected recent papers authored or co-authored by Infante include:

  • "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study" (2021, The Lancet)
  • "Teclistamab, a B-cell maturation antigen×CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study" (2021, The Lancet)
  • "Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma" (2020, Clinical Cancer Research)
  • "First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors" (2021, EClinicalMedicine)
  • "Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53" (2021, Clinical Cancer Research)

Best Publications

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesus G Berdeja;Deepu Madduri;Saad Z Usmani;Andrzej Jakubowiak

  • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

    Gerald S Falchook;Georgina V Long;Georgina V Long;Razelle Kurzrock;Kevin B Kim

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

    Andrea B. Apolo;Jeffrey R. Infante;Ani Balmanoukian;Manish R. Patel

  • Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Manish R. Patel;John Ellerton;Jeffrey R. Infante;Manish Agrawal

  • Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    Jeffrey R. Infante;Leslie A. Fecher;Gerald S. Falchook;Sujatha Nallapareddy

  • Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

    David F. McDermott;Jeffrey A. Sosman;Mario Sznol;Christophe Massard

  • Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    Kevin B. Kim;Richard Kefford;Anna C. Pavlick;Jeffrey R. Infante

  • Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

    Hans J. Hammers;Elizabeth R. Plimack;Jeffrey R. Infante;Brian I. Rini

  • Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic Adenocarcinoma

    Jeffrey R. Infante;Hiroyuki Matsubayashi;Norihiro Sato;James Tonascia

  • Targeting CDK4/6 in patients with cancer

    Erika Hamilton;Jeffrey R. Infante

  • A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

    Jeffrey R. Infante;Bradley G. Somer;Joon Oh Park;Chung-Pin Li;Chung-Pin Li

  • Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

    Josep Tabernero;Rastislav Bahleda;Rodrigo Dienstmann;Jeffrey R. Infante

  • Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

    Kevin D. Courtney;Jeffrey R. Infante;Elaine T. Lam;Robert A. Figlin

  • Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

    R. Kefford;H. Arkenau;M. P. Brown;M. Millward

  • First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Ryan J. Sullivan;Jeffrey R. Infante;Filip Janku;Deborah Jean Lee Wong

  • Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

    Georgina Long;Jeffrey s Weber;Jeffrey R Infante;Kevin B Kim

  • A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas

    Jeffrey R. Infante;Phillippe A. Cassier;John F. Gerecitano;Petronella O. Witteveen

Frequent Co-Authors

Howard A. Burris
Howard A. Burris Sarah Cannon Research Institute
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Patricia LoRusso
Patricia LoRusso Yale University
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Kathleen N. Moore
Kathleen N. Moore University of Oklahoma Health Sciences Center
Daniel D. Von Hoff
Daniel D. Von Hoff Translational Genomics Research Institute
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University
Keith T. Flaherty
Keith T. Flaherty Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always require a traditional MD program. Many students find rewarding roles through alternative online degrees, especially in nursing, healthcare administration, and health information management.

For those interested in administrative healthcare roles, earning a certification in medical coding can open doors. The medical billing and coding certification cost varies, but affordable online options make this career path highly accessible.

Nursing is one of the most dynamic healthcare fields. Students looking to become Nurse Practitioners can benefit from the cheapest nurse practitioner programs available online. Similarly, exploring cheap online nursing programs helps reduce the financial barriers for future Registered Nurses.

For advanced nursing professionals, earning an online PhD in nursing can lead to roles in research, leadership, or academia—all while balancing work and study through flexible, accredited programs.

Best Scientists Citing Jeffrey R. Infante

Trending Scientists

Recently Published Articles